Identification of the molecular subtypes of tumors using gene expression may allow a better understanding of their biology and patient-specific treatment: For instance, patients with gliomas with mutation of isocitrate dehydrogenase 1 gene (IDH1) or IDH2 had better outcomes that those with wild-type IDH genes8. This evidence concerns the gene IDH1 and central nervous system cancer.